A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation
Jennifer L. Crombie(Dana-Farber Cancer Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Jon Arnason(Beth Israel Deaconess Medical Center), Josie Montegaard(Dana-Farber Cancer Institute), Erin M. Parry(Broad Institute), Shruti Bhandari(Eastern Maine Medical Center), Christine E. Ryan(Dana-Farber Cancer Institute), Jacob D. Soumerai(Harvard University), David C. Fisher(Dana-Farber Cancer Institute), Celeste Carey(Dana-Farber Cancer Institute), Aaron Zou(Dana-Farber Cancer Institute), Samantha Normilus(Dana-Farber Cancer Institute), Alvaro J. Alencar(University of Miami), Y. Ren(Dana-Farber Cancer Institute), Philippe Armand(Dana-Farber Cancer Institute), Austin I. Kim(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute), Svitlana Tyekucheva(Harvard University)
Cited by 0
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
Small molecules, big impact: 20 years of targeted therapy in oncology
|The Lancet|2020|606
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595